Clinical and molecular response to alpha1-oleate treatment in patients with bladder cancer
Background: The tumoricidal complex alpha1-oleate targets bladder cancer cells, triggering rapid, apoptosis-like tumor cell death. Clinical effects of alpha1-oleate were recently observed in patients with non-muscle invasive bladder cancer (NMIBC), using a randomized, placebo-controlled study protocol. Aims: To investigate if there are dose-dependent effects of alpha1-oleate. Materials and Methods